Market Research Report Chemotherapy Induced Neutropenia Market Report

Chemotherapy Induced Neutropenia (CIN) Market
Insights and Market Forecast Report 2023
Market Research Hub (MRH) has recently announced the addition of a fresh report,
titled “Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology
and Market Forecast-2023” to its report offerings. The report is built using data and
information sourced from proprietary databases, primary and secondary research and
in-house Forecast model analysis by Publisher team of industry experts.
Request for Sample Report:
http://www.marketresearchhub.com/enquiry.php?type=S&repid=1045347
DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights,
Epidemiology and Market Forecast-2023” Report provides an overview of the
disease and global market trends of the Chemotherapy Induced Neutropenia for the
seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK)
and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report
covers the therapeutics market revenue, treatment practice and Chemotherapy
Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented
by seven major markets. In addition, the report provides the historical and forecasted
data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10
Cancer indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e. Breast
Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic
Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin
Lymphoma), who are at risk of developing CIN as an adverse event of the
chemotherapies of respective cancers. Neupogen (Filgrastim), developed and
marketed by Amgen is the first G-CSF approved for chemotherapy-induced
neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved